Bayer Animal Health, Nutreco to enhance nutritional health of farm animalsMay 21, 2019Bayer Animal Health and Nutreco are combining their efforts to improve the nutritional and health performance of farm animals. The companies have signed a global research and development collaboration agreement. Their first project together will be to come up with innovative solutions for gastrointestinal health in dairy and beef cattle. "The agreement further demonstrates our strong commitment to drive innovation in the farm animal space," says Douglas Hutchens, DVM, PhD, Bayer's head of drug discovery, external innovation and chief veterinary officer. "Joining forces with Nutreco will increase our innovative capabilities and leverage the development of new solutions for our customers. We look forward to furthering farm animal health and well-being, and contributing to the sustainable development of the dairy and beef cattle industry." The project will be run by Trouw Nutrition. "We're excited to be partnering with a company like Bayer to bring real breakthroughs in this area," says Trouw Nutrition innovation director, Saskia Korink. "By pooling our know-how and capabilities, we can truly make significant steps forward and support farmers in growing their business in a sustainable way with animal well-being as a priority."
SPONSORED CONTENTProtect your patients from the start.Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is the first monthly preventative of its kind. Combining three ingredients for month-long protection. + Learn more
Bayer, adivo to develop therapeutic antibodiesApril 17, 2019Bayer Animal Health and adivo have signed an agreement to develop therapeutic antibodies for companion animals. The collaboration may be good news for veterinary medicine. Although the use of therapeutic antibodies is not widespread, they offer a variety of healing options for diseases that still cannot be treated with current technology. "Today's agreement is another example of how we realize our innovation strategy," says Douglas Hutchens, DVM, PhD, Bayer Animal Health's head of drug discovery, external innovation and chief veterinary officer. "By combining the know-how from creative start-up companies like adivo with opportunities derived from Bayer's research, we broaden our space of therapeutic medicine options and complement our portfolio. We are constantly looking for innovative technologies enabling us to generate novel treatment options for the companion animal sector. Now, we will focus on evolving the options presented by adivo from research and development to market maturity." Under the terms of the agreement, Bayer will have access to adivo's species-specific monoclonal antibody technology, which uses an exclusive fully canine phage display library. Bayer will provide targets involved in severe animal diseases. "At adivo, we truly believe pets have a positive impact on our society," says the company's managing director, Kathrin …
Bayer, ParaTheraTech partner to improve treatment of early-life diarrhea in calvesDecember 18, 2018A new licensing agreement will help farmers and veterinarians fight early-life diarrhea in dairy and beef cattle. Bayer Animal Health and ParaTheraTech (PTT) have signed a global agreement to advance new Cryptosporidiosis treatment options for these farm animals.
Bayer to leave animal health marketDecember 7, 2018A longtime player in animal health care is leaving the industry. In 2019, Bayer Animal Health will make pharmaceuticals, consumer health, and crop science primary focus areas.
Bayer, NeuroCycle partner to advance pet allergy treatmentsSeptember 18, 2018Bayer Animal Health and NeuroCycle Therapeutics Inc. have signed a global license agreement to advance allergy treatment options for companion animals. As part of the license agreement, Bayer will develop and commercialize novel compounds based on NeuroCycle's intellectual property. "[This] agreement underlines our strategy to combine the know-how from creative startup companies like NeuroCycle with opportunities derived from Bayer's research," said Douglas Hutchens, DVM, PhD, Bayer Animal Health's head of drug discovery, external innovation and chief veterinary officer. "It is a major milestone on our way to complementing our portfolio with novel treatment options against allergic diseases for the companion animal sector." The companies' goal is to maximize the humanitarian impact of their innovative technologies, according to Jed Hubbs, PhD, MS, CEO of NeuroCycle Therapeutics.
Veterinary practice trends webinar highlights further industry consolidationAugust 17, 2018In just five years, 25 percent of veterinary practices, accounting for half of all veterinary visits, will be corporately owned, according to Brakke Consulting. During a webinar presented at the end of June, "Hot Topics in Veterinary Practice," Brakke senior consultant John Volk said myriad variables were contributing to the trend: looming mass veterinarian retirement, fewer vets wanting to own practices, low interest rates and high interest for investors, and more. The webinar also discussed the largest veterinary consolidators; Banfield Pet Hospital and VCA lead the way with nearly 2,000 practices; National Veterinary Associates counts more than 400 clinics, and VetCor has more than 200. Something corporate outfits can offer that consumers want is the convenience of pet health plans, which allow pet owners to pay in regular installments, increase clinic visits and revenue, improve patient care, attract new clients, and build a bond between the practice and the client. To counteract corporate sales, Volk said associates should work with a current owner, partner with others, and focus on one- and two-doctor practices. Other sectors of the profession mimic the consolidation trend. The top five animal drug manufacturers, Bayer Animal Health, Boehringer Ingelheim, Elanco Animal Health, …
FDA approves sale of Baytril soft chew formulationAugust 6, 2018The U.S. Food and Drug Administration has approved for sale Bayer Animal Health's Baytril Soft Chewable Tablets, based on a soft-chew formulation by Piedmont Animal Health, as a new option for administering enrofloxacin to cats and dogs. The antibiotic has been used for 30 years in tablet form to treat bacteria that cause skin, urinary, respiratory, and other infections. Piedmont's soft chew uses meat-free cubes made without water, heat, or an extrusion process so they can be stably infused with active pharmaceutical ingredients. Bayer also uses Piedmont's soft chew for Advantus canine oral flea medicine and Quellin canine pain reliever and anti-inflammatory. Claro, a single-application treatment for canine otitis externa, gives Bayer four FDA-approved products in the last five years. Piedmont said it will gain FDA approval for 10 or more products in the next five years. "I fully expect that Piedmont's current portfolio of proprietary drugs will significantly grow and disrupt the indication areas we are targeting," said Roland Johnson, the company's founder and CEO. "This (Baytril) approval is yet another stepping stone toward that objective."
Bayer, Mitsui Chemicals Agro to develop novel parasiticides for petsJuly 9, 2018Bayer Animal Health GmbH and Mitsui Chemicals Agro Inc. (MCAG) have signed a global license agreement in which Bayer will develop novel companion animal parasiticide compounds based on MCAG's intellectual property. Further terms of the agreement were not disclosed. "At Bayer, we passionately care for the health and well-being of animals," said Dr. Dirk Ehle, head of Bayer Animal Health. "And we have long been committed to help pet owners protect their animals from parasites. Today we have taken an important next step to further deliver on this commitment to our customers." "This license agreement combines the strong science base within Bayer with innovative chemistry from MCAG," said Dr. Sabine Bongaerts, head of Bayer drug discovery. "It will enable us to further expand our strong portfolio of parasiticides in the companion animal sector and deliver new compelling products to our customers." "Under the concept of technology and innovation, MCAG has been providing its innovative products and services to the customers in agrochemicals and environmental health businesses for many years so far," said Satoshi Ozawa, president and CEO of MCAG. "Now, through close and successful collaboration with Bayer in the animal health sector, we …
